| Literature DB >> 34050477 |
Ryo Nishihara1, Koji Suzuki1, Sung-Bae Kim2, Ramasamy Paulmurugan3.
Abstract
The present protocol demonstrates a novel mammalian cell imaging platform exerting a bioluminescence resonance energy transfer (BRET) system. This platform achieves a ~300 nm blue-to-near infrared shift of the emission (NIR-BRET) with the development of a unique coelenterazine (CTZ) derivative named BBlue2.3 and a fusion reporter protein probe named iRFP-RLuc8.6-535SG. The best NIR-BRET shift was achieved by tuning the blue emission peak of BBlue2.3 to a Soret band of the iRFP. In mammalian cells, BBlue2.3 emits light that is ~50-fold brighter than DeepBlueC in cell imaging when combined with RLuc8.6-535SG. This NIR-BRET platform is sufficiently brighter to be used for imaging live mammalian cells at single-cell level, and also for imaging metastases in deep tissues in live mice without generating considerable autoluminescence. This unique optical platform provides the brightest NIR-BLI template that can be used for imaging a diverse group of cellular events in living subjects.Entities:
Keywords: Bioluminescence imaging (BLI); Bioluminescence resonance energy transfer (BRET); Blue-to-near infrared shift; Coelenterazine derivatives; Metastasis
Year: 2021 PMID: 34050477 DOI: 10.1007/978-1-0716-1258-3_21
Source DB: PubMed Journal: Methods Mol Biol ISSN: 1064-3745